CitruSlim® combines standardized Citrus bergamia Risso fruit extract with standardized Eurycoma longifolia root extract, bringing together two distinct approaches to weight management: bergamot-derived metabolic support and Eurycoma-derived stress/adaptation support.
CitruSlim® is a standardized proprietary blend of:
The clinical formulation contained 83.33% Bergamonte® citrus bergamot and 16.67% Adapticort® Eurycoma longifolia.
The bergamot component provided the characteristic bergamot flavanone complex together with pectins and vitamin C, while the Eurycoma longifolia component provided standardized eurypeptides and glycosaponins.
CitruSlim® was developed specifically around the interconnected areas of body-weight management, metabolic function and physiological stress response.
The formulation evaluated in the published human clinical study was:
Component | CitruSlim® Composition |
Bergamonte® Citrus bergamia fruit extract | 83.33% |
Adapticort® Eurycoma longifolia root extract | 16.67% |
The bergamot component was standardized to its characteristic flavanones — neoeriocitrin, naringin, neohesperidin, melitidin and brutieridin — and also contained 8% pectins and 8% vitamin C.
The Eurycoma longifolia component was standardized to 22% eurypeptides and 40% glycosaponins.
Weight management is more complex than simply reducing caloric intake.
Body weight can be influenced by interconnected factors including:
CitruSlim® brings together two botanicals with complementary research backgrounds.
Bergamot provides a polyphenol-rich metabolic component, while Eurycoma longifolia provides an adaptogenic component relevant to physiological stress and cortisol.
This creates a differentiated approach to metabolic + stress-related weight management.
Chronic stress can affect appetite, eating behavior, sleep and metabolic function. Cortisol is one of the principal hormones involved in the physiological stress response.
The CitruSlim® clinical paper specifically notes the relationship between elevated cortisol, stress, appetite and weight gain.
This provides part of the rationale for combining the metabolic properties of bergamot with the stress-response properties of Eurycoma longifolia.
Bergamonte® provides the citrus bergamot component of the formulation.
Authentic Citrus bergamia contains a distinctive flavanone profile including:
Bergamot polyphenols have been investigated for effects related to lipid and glucose metabolism, while the full-spectrum bergamot formulation used in previous research was also associated with body-weight and BMI reductions.
CitruSlim® uses this metabolic platform as the major component of the formulation.
Adapticort® provides the standardized Eurycoma longifolia root extract component.
The clinical rationale is particularly relevant to stress adaptation and cortisol balance.
In an independent randomized human study, a standardized Eurycoma longifolia root extract was evaluated in 63 moderately stressed men and women for four weeks. The study reported a 16% reduction in cortisol exposure and a 37% increase in testosterone status, together with improvements in tension, anger and confusion.
CitruSlim® therefore combines a metabolic botanical platform with an adaptogenic component relevant to the physiological stress response.
Weight Management + Metabolic Support + Stress Adaptation
CitruSlim® is particularly relevant to formulations targeting:
Its primary commercial differentiation is that the finished CitruSlim® combination itself has been clinically studied for weight management.
Yes.
CitruSlim® was evaluated in:
Hancke J, Srivastava S, Caceres DD, Burgos RA, Alarcon P. “An exploratory double-blind, randomized, placebo-controlled study to assess the efficacy of CitruSlim on body composition and lipid parameters in obese individuals.” Phytotherapy Research. DOI: 10.1002/ptr.7331.
The study was funded by HP Ingredients Corporation and evaluated CitruSlim® specifically for body-weight management in overweight and obese individuals.
Who They Studied
The study recruited male and female adults aged 18–60 years with a BMI between 25 and 35 kg/m² and normal liver and renal function.
Participants also met defined metabolic-risk criteria.
A total of 97 participants were initially allocated/randomized, with the study ultimately reporting three treatment groups.
What They Did
This was an exploratory, randomized, double-blind, placebo-controlled clinical study lasting 112 days — 16 weeks.
Participants were assigned to:
The treatment arms used capsules containing:
Participants took one capsule three times daily before breakfast, lunch and dinner.
This means the actual daily CitruSlim® intake was:
Group | Per Capsule | Daily CitruSlim® |
Low Dose | 200 mg | 600 mg/day |
High Dose | 400 mg | 1,200 mg/day |
Placebo | — | 0 mg/day |
What They Measured
The primary objective was to evaluate body composition using DXA.
Researchers measured:
Secondary endpoints included:
This was therefore substantially more comprehensive than simply measuring scale weight.
Participants followed a defined lifestyle program.
They maintained a 1,200–1,500 calorie/day diet and were asked to perform 30–60 minutes of light-intensity exercise daily. Treatment compliance exceeded 90%.
Importantly, the placebo group followed the same general lifestyle program.
The investigators noted that diet and exercise compliance was similar between groups, while the placebo group did not show a significant BMI reduction from baseline.
What They Found
After 112 days, both CitruSlim® doses produced significant reductions in BMI from baseline:
The placebo group showed a nonsignificant increase in BMI.
Importantly, the differences between both CitruSlim® groups and placebo were statistically significant (p < 0.001).
What It Means
The principal clinical finding is straightforward:
CitruSlim® significantly reduced BMI compared with placebo after 112 days.
Both 600 mg/day and 1,200 mg/day produced significant effects.
Yes.
The authors concluded that the study findings supported the efficacy of CitruSlim® in reducing body weight in obese participants.
The BMI results are particularly important because they were significant versus placebo, rather than simply representing a within-group change over time.
No clear dose-response advantage was demonstrated for BMI.
At day 112:
Both were significant compared with placebo.
From a formulation perspective, this makes the 600 mg/day clinically studied dose particularly noteworthy, because the lower dose produced a BMI response of similar magnitude to the higher dose in this exploratory trial.
The study did not demonstrate a significant difference versus placebo for body-fat percentage as measured by DXA.
Similarly, significant between-group effects were not demonstrated for:
The authors explicitly reported these as nonsignificant findings.
CitruSlim® should therefore be positioned primarily around its demonstrated body-weight/BMI results, rather than claiming clinically demonstrated changes in body-fat percentage or lean mass.
Not significantly compared with placebo in this particular trial.
The investigators reported no significant improvement in lipid profile at the end of the trial compared with placebo.
This distinction is important because bergamot itself has a substantial research history in lipid metabolism, but the CitruSlim® study population, dose and study design should not be conflated with the separate BPF® cholesterol studies.
For CitruSlim®, the strongest direct clinical positioning is weight management and BMI.
The low-dose CitruSlim® group showed a significant reduction in cortisol compared with baseline.
This is scientifically interesting because CitruSlim® contains standardized Eurycoma longifolia, which has an independent human clinical research history in stress-hormone regulation.
However, the CitruSlim® cortisol finding should be kept distinct from the stronger placebo-controlled BMI finding.
The study provides mechanistic support for the Adapticort® side of the formulation.
Researchers studied 63 moderately stressed adults receiving standardized Eurycoma longifolia root extract or placebo for four weeks.
Results included:
The study did not, however, find significant changes in body weight or body-fat percentage during those four weeks.
The relevance to CitruSlim® is therefore stress adaptation and hormonal response, not independent proof that Eurycoma longifolia alone causes weight loss.
Yes.
A separate randomized, double-blind trial evaluated a pectin-enriched bergamot polyphenol formulation (BPE-C) at 650 mg/day and 1,300 mg/day for 90 days in adults with metabolic syndrome.
The high-dose group demonstrated:
The effects generally demonstrated a dose-dependent tendency.
This provides additional human evidence supporting the bergamot side of the CitruSlim® formulation, although it is separate from the clinical trial conducted on CitruSlim® itself.
The two studies provide complementary evidence.
BPE-Complex® research
Demonstrated effects involving:
Weight + BMI + glucose + insulin resistance + lipid metabolism + appetite-related hormones.
Eurycoma longifolia research
Demonstrated effects involving:
Cortisol + testosterone + stress-related mood parameters.
CitruSlim® research
Then clinically tested the combination strategy and demonstrated:
Significant BMI reduction versus placebo at both 600 mg/day and 1,200 mg/day.
This creates a logical research progression from the individual botanical platforms to the finished CitruSlim® combination.
CitruSlim® approaches weight management through two complementary physiological areas:
METABOLIC SUPPORT
Bergamonte®
Bergamot polyphenols have been investigated in relation to:
STRESS ADAPTATION
Adapticort®
Standardized Eurycoma longifolia has been investigated in relation to:
CitruSlim® brings these two systems together in one clinically studied formulation.
The CitruSlim® study measured ghrelin, a hormone involved in appetite regulation.
Ghrelin increased from baseline in the CitruSlim® groups, but the changes were not statistically significant compared with placebo at day 112. The authors specifically stated that the effect of CitruSlim® on ghrelin and body weight remained debatable.
Therefore, CitruSlim® should not be characterized as a clinically proven appetite suppressant based on this study.
The low-dose CitruSlim® group showed a significant reduction in fasting glucose compared with baseline, but the same effect was not observed in the high-dose group.
The researchers noted that baseline mean fasting glucose was already within the normal range and suggested that inter-individual variability may have contributed to the findings.
The more robust clinical positioning remains weight management/BMI, rather than glucose control.
Yes. The study characterized CitruSlim® as well tolerated.
There were no clinically significant between-group differences in several safety parameters, including:
Values remained within reference ranges.
Adverse events were reported across the study groups and were principally gastrointestinal or other isolated events.
Two daily doses were clinically studied:
600 mg/day
200 mg CitruSlim® taken three times daily.
1,200 mg/day
400 mg CitruSlim® taken three times daily.
Both were administered before meals for 112 days, and both produced significant BMI reductions compared with placebo.
The 600 mg/day dose is particularly relevant because it achieved a statistically significant reduction in BMI versus placebo while using half the daily quantity of the high-dose group.
At day 112, BMI reductions were very similar:
600 mg/day: −3.2%
1,200 mg/day: −3.3%
This provides formulators with a clinically studied 600 mg/day weight-management dose suitable for practical capsule and multi-ingredient formulations.
CitruSlim® is a botanical formulation based on citrus bergamot and Eurycoma longifolia rather than a conventional stimulant approach.
Its research focuses on:
Body weight + BMI + metabolism + stress adaptation
rather than thermogenic stimulation.
That makes CitruSlim® particularly relevant to formulations designed around longer-term metabolic weight management and stress resilience.
The strongest direct positioning is:
Clinically Studied Weight Management
supported by a randomized, double-blind, placebo-controlled study demonstrating significant BMI reductions at 600 mg/day and 1,200 mg/day over 112 days.
A broader secondary scientific story can then explain why the formulation combines:
Bergamot → metabolic support
with
Eurycoma longifolia → stress adaptation
This is a stronger and more scientifically disciplined positioning than attempting to make CitruSlim® primarily a cholesterol, glucose, appetite-suppression or body-fat ingredient.
CitruSlim® is available through HP Ingredients for manufacturers and product developers seeking a clinically studied botanical weight-management ingredient.
Qualified formulators can request:
CitruSlim® provides a differentiated formulation strategy by combining standardized Calabrian citrus bergamot with standardized Eurycoma longifolia in a finished ingredient clinically studied for body-weight management and BMI reduction.
